GSK-3 is a 10-valent pneumococcal polysaccharide and non-typeable Haemophilus influenzae protein D conjugate vaccine, which also includes the conserved, unconjugated pneumococcal proteins dPly and PhtD. dPly is a thiol-dependent toxin, while PhtD is a protein which is exposed on the surface of intact bacteria, and vaccines based on these proteins have the potential to provide broader protection against pneumococcal disease.
GSK-3’s (10-valent recombinant-conjugate pneumococcal vaccine; GlaxoSmithKline) novel vaccine approach and potential for broader
coverage will make it a strong contender on the market, but it will face significant competition from Prevnar 13 (13-valent
pneumococcal conjugate vaccine; Pfizer), as well as pipeline vaccines V114 (15-valent pneumococcal conjugate vaccine; Merck & Co)
and PF-06482077 (20-valent pneumococcal conjugate vaccine; Pfizer), which also aim to provide broader protection.
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.